Bdellin-HM-2
Non-classical Kazal-type protease inhibitor from Hirudinaria manillensis — prolongs aPTT without inhibiting trypsin, thrombin, FXa, FXIIa, or kallikrein (Cheng 2019).
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Non-classical Kazal-type protease inhibitor from Hirudinaria manillensis — prolongs aPTT without inhibiting trypsin, thrombin, FXa, FXIIa, or kallikrein (Cheng 2019).
- Evidence level
- In vitro
- Drug vs leech
- Purified natural compound
- Safety domains
- Bleeding
Clinical translation limit
Bdellin-HM-2's in vitro aPTT-prolonging activity does NOT establish clinical anticoagulant efficacy. No FDA-approved derivative exists; H. manillensis is not the FDA-cleared K040187 medicinal leech species. The molecular target remains uncharacterized despite the demonstrated phenotypic anticoagulant effect.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Molecular weight
- 14,000 Da
- Source species
- Hirudinaria manillensis
- Discovered
- 2019 · Cheng RM et al.
Biological Targets
- → aPTT-prolonging anticoagulant mechanism (non-classical, target unidentified)
Key Citations
- Cheng RM et al. (2019), Zool Res · PMID 31011131
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.